Dr. John Herrmann
John Herrmann is a Partner and SVP, Oncology with Catenion Inc., Boston and lives in Winchester MA adjacent to the energetic biotech corridor of Cambridge/Boston.
- Chief Strategy Officer and SVP Oncology, Elstar Therapeutics
- Chief Scientific Officer, External Innovation, Eli Lilly & Co.
- Dir. Search & Evaluation (Serono/Merck-KGaA)
- SVP Discovery, CEPTYR Inc.
- Head of Oncology, CuraGen Corp.
John earned his Ph.D. in Cancer Biology from The University of Texas MD Anderson Cancer Center. His dissertation studies explored molecular mechanisms of melanoma metastasis to the central nervous system.
Following his post-doctoral studies on bcl-2 mediated drug resistance and the ubiquitin-proteasome system as a drug target including a collaboration with Proscript/Leukocyte/Millennium to understand the medical potential for PS-341 (Bortezomib/Velcade™) John was promoted to a junior research faculty at UTMDACC.
- Asset/company search & evaluation
- Competitive product positioning strategy
- Emerging drug target space and format analysis
- Competitive intelligence
- Major bio/pharma situational strategies
- Clinical trials & regulatory
In his free time, John enjoys skiing with his family/friends, fitness activities and reading books and articles on improving business strategy.
Arno Heuermann is a founding Partner of Catenion who lives in Berlin, Germany. Arno has ten years of experience as CEO and COO. He has managed companies in Germany, France and Luxemburg.
While working on his degrees, Arno founded a technical engineering office in 1994. He continued to follow the entrepreneurial path in 1998 by founding Biopsytec GmbH, a DNA diagnostics company focused on agriculture, heading the company for more than five years as Managing Director.
In 1999, he co–founded Epigenomics AG, a public biotech company focused on DNA methylation, later remaining as an advisor and member of the firm’s Supervisory Board.
In August 2000, Arno orchestrated the founding and financing of Biopsytec Holding AG, thus merging Genious SA and the QTL AG and Biopsytec GmbH. He managed Biopsytec Holding AG for the next three years before helping launch Catenion in 2003. Since that time, he has been Catenion’s chief operating officer.
He is experienced in the diverse practices of patent management and has made numerous successful inventions.
Arno Heuermann is married and has two children. He is a lover of classical music, country life and horseback riding.
Arno holds a diploma degree in process engineering from the Technical University of Applied Sciences in Berlin. In addition, Arno attended the Berlin business school for Industrial Engineering and Management.
- Management of biotech and diagnostic companies
- Company and venture financing
- Patent writing, filing and strategy
- Business plan development and evaluation
Dr. Matthias Krings
Matthias Krings is a founding Partner of Catenion who lives in Munich, Germany. Matthias became a consultant in 1999 at Mercer Management Consulting and later joined a strategy consulting boutique, Theron. In 2003, he co-founded Catenion.
Matthias has worked for European and global client organisations in Pharma, MedTech and Biotech strategy with a particular focus on R&D portfolio management. He has co-developed and applied specialised approaches and tools to assess and mitigate the technical and scientific risks of pharmaceutical and medical device R&D projects, and has linked these methods and tools to portfolio-level decision-making and corporate strategy. Matthias continuously helps clients master Catenion’s consulting approaches and embed them into management routines.
Since 2007 Matthias has headed the executive training and education unit of Catenion, The Catenion Academy, with the goal of significantly improving the way clients manage R&D, value assets, develop project teams and corporate strategies in Pharma, MedTech and Biotech.
In private, Matthias enjoys a variety of music, gardening, cooking, and water sports and is interested in human evolution and evolutionary psychology.
Before commencing his studies, Matthias lived and worked in Florida for a year. He holds a diploma and a doctorate degree in biology from the Ludwig-Maximilians University in Munich. His PhD work was supported by a scholarship from the Boehringer Ingelheim Fonds, Foundation for Basic Research in Medicine. While in Academia, Matthias made significant scientific contributions to the field of human evolution. Matthias’ and his fellow researchers’ analysis of the first-ever DNA sequence from the Neanderthal type-specimen in 1997 continues to be one of the most frequently cited papers in the field of evolution. This study was a major breakthrough and paved the way for further studies on Neanderthal DNA. Recent technological advances have led to the retrieval of entire nuclear genomes of Neanderthals and other pleistocene hominins by Matthias’ former colleagues. It is now established that there was a limited degree of interbreeding between modern humans, Neanderthals and the recently identified group of Denisovans.
- Corporate and R&D strategy development
- Portfolio Management in Pharma and Medical Devices
- Organisational development
- Change management
- R&D asset valuation
- R&D organisation & process design
- Due diligences in licensing & M&A context
- Technology and research rtrategy
- Knowledge and Innovation Management
- Diagnostics / Pharmacodiagnostics
- Biotech business modelling
- Post-merger integration
- Launch management
Matthias co–authored Catenion’s Commentaries “Elements of Winning Strategies in R&D” and “Recombinant Portfolio Management — Recognising and Enabling Innovation”. They are part of Catenion’s “Shaping Pharmaceutical Strategy” series that focuses on high–profile issues for the industry.
Dr. Markus Thunecke
Markus Thunecke is a founding Senior Partner of Catenion who lives in Berlin, Germany. Markus started his consulting career in 1997 at Mercer Management Consulting before joining a strategy consulting boutique, Theron, and setting up Catenion in 2003.
Markus has helped numerous clients around the globe in the pharmaceutical and medical products industries create competitive advantage. In addition to his work on strategy, he specialises in developing leading–edge analytical tools and combining them with organisational development capabilities. Markus is the developer of a number of Catenion’s proprietary tools for portfolio management and risk assessment. In recent engagements, Markus has helped clients develop and realign their R&D strategies, review their discovery and development portfolios, and create organisational models that foster innovation.
He is a frequent speaker at conferences on R&D strategy and portfolio management.
Markus holds a PhD in biochemistry from the University of Heidelberg, where he generated transgenic animal models for Alzheimer’s disease. He also has three years of research experience within the CNS field at Schering AG.
- Value management
- Company strategy development
- Portfolio management/Decision analysis
- Technology and research strategy
- Biotech business models
- Organisation and process design
- Knowledge and innovation management
- Executive training and coaching
Markus has written several Catenion Commentaries including “Risk Profiles of Corporate Portfolio Strategies” as well as “Elements of Winning Strategies in R&D”, “Recombinant Innovation Management (RIM) – How to Stimulate Breakthrough Innovation within Large R&D Organisations”, “Recombinant Portfolio Management – Recognising and Enabling Innovation”. He also co–authored “Zero Base R&D” and “The Challenge for Japan’s Pharmaceutical Top Twenty”. All of them are part of Catenion’s “Shaping Pharmaceutical Strategy” series that focuses on high–profile issues for the industry.
Christian Elze is a founding partner of Catenion and has been developing the company’s business in Japan since 2008. He holds a BSc from the London School of Economics and an MBA from Columbia University
Christian is working with companies, universities and governments in the field of biomedical innovation
In his work Christian is focusing on how translational research and the changing nature of biopharma innovation are re-shaping the respective roles of funding agencies, biopharma companies and academia in the research and development of new drugs
Besides his consulting work, Christian frequently speaks about Emerging Technologies, Healthcare Reform, Pricing & Reimbursement, Biomedical Innovation, as well as Translational Research at industry conferences and universities in Japan, the US and Europe
Christian is a fluent speaker of German, English, French, Russian, Italian, Portuguese and Spanish, he lives with his family in London